sirflox

SIRFLOX data presented at ASCO 2015 by Professor Peter Gibbs, The Royal Melbourne Hospital, Australia, Co-Principal Investigator

SIRFLOX key findings

SIR-Spheres Y-90 resin microspheres + mFOLFOX6 (+ bev*) in mCRC

  • Statistically significant improvement of 7.9 months in median PFS in the liver,
    from 12.6 to 20.5 months
  • 31% reduction in risk of progression in the liver
  • 3-fold increase in complete response rate in the liver
  • Statistically significant increase in hepatic response rate

Working better together in the liver

 

Progression-Free Survival in the liver

SIR-Spheres Y-90 resin microspheres significantly extend PFS in the liver with a 31% reduction in risk of progression in the liver

PFS in the liver

Objective Response Rate (ORR) in the liver

SIR-Spheres Y-90 resin microspheres significantly increase Objective Response and Complete Response Rates in the liver

Response rate in the liver

SIR-Spheres Y-90 resin microspheres – the only SIRT supported by Level 1 evidence.

 

bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)